Teva Pharmaceutical Industries, a global generic drug maker, has acquired Cephalon.
Following the merger agreement between the parties, each share of Cephalon common stock has been converted into the right to receive $81.50 in cash.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Teva president and CEO Shlomo Yanai said the deal would strengthen their specialty pharmaceuticals business through diversification and expansion of their product.
"Our newly-expanded portfolio in CNS, Oncology, Respiratory and Women’s Health, along with our robust pipeline of more than 30 late-stage products truly cements our position as a leader in specialty pharma," Yanai added.
Teva expects the acquisition to be immediately accretive to Teva’s non-GAAP earnings per share and accretive to Teva’s GAAP earnings within the fourth quarter of closing.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
